GlassScriptPhysician profile
Mary Baird
NPI 1578341863
$9,604.80
in general payments reported to CMS, 2019-2025
50 companies · $5,539 in 2025
The $5,539 reported for 2025 was more than what 98% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $555 · 2024: $3,510 · 2025: $5,539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,937 · Long Term Medical Supply Or Device Loan: $1,696 · Education: $972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,936.54 |
| Long Term Medical Supply Or Device Loan | $1,696.38 |
| Education | $971.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,423.37 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $583.32 | 2023-2025 | Calquence, Enhertu, Lynparza |
| Merck Sharp & Dohme LLC | $555.06 | 2023-2025 | Keytruda, Welireg, Keytruda Qlex |
| Incyte Corporation | $441.23 | 2023-2025 | Jakafi, Zynyz, Monjuvi |
| Janssen Biotech, INC. | $362.83 | 2024-2025 | Erleada, Balversa, Darzalex |
| Daiichi Sankyo INC. | $343.32 | 2024-2025 | Enhertu, Injectafer |
| Abbvie INC. | $336.15 | 2024-2025 | |
| Pfizer INC. | $280.41 | 2024-2025 | |
| Glaxosmithkline, LLC. | $269.01 | 2023-2025 | Zejula, Jemperli, Ojjaara |
| Genentech USA, INC. | $265.77 | 2024-2025 | Itovebi, Tecentriq, Venclexta |
| E.R. Squibb & Sons, L.L.C. | $190.50 | 2023-2025 | Opdivo, Opdualag |
| Celgene Corporation | $185.05 | 2024-2025 | Reblozyl, Opdivo |
| Regeneron Healthcare Solutions, INC. | $178.31 | 2023-2025 | Libtayo |
| Jazz Pharmaceuticals INC. | $167.22 | 2023-2025 | Zepzelca |
| Exelixis INC. | $166.42 | 2024-2025 | Cabometyx |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $154.99 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $148.41 | 2024-2025 | |
| Gilead Sciences, INC. | $141.65 | 2024-2025 | Trodelvy |
| Astellas Pharma US INC | $139.93 | 2024-2025 | Vyloy, Padcev |
| Eagle Pharmaceuticals, INC. | $137.14 | 2024 | |
| Genmab U.S., INC. | $134.94 | 2024-2025 | Epkinly, Tivdak |
| Lilly USA, LLC | $128.29 | 2023-2025 | Jaypirca, Verzenio |
| Seagen INC. | $121.32 | 2023-2025 | Adcetris |
| Takeda Pharmaceuticals U.S.A., INC. | $120.49 | 2024-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Acrotech Biopharma INC. | $103.91 | 2024-2025 | Beleodaq |
| Ipsen Biopharmaceuticals, INC | $102.92 | 2023-2025 | Onivyde, Somatuline Depot |
| Puma Biotechnology, INC. | $95.52 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $93.71 | 2024-2025 | Ultomiris |
| Servier Pharmaceuticals LLC | $92.30 | 2024-2025 | |
| Stemline Therapeutics INC. | $89.43 | 2025 | Orserdu |
| Pharmacosmos Therapeutics INC. | $88.42 | 2024-2025 | Monoferric |
| Array Biopharma INC | $87.17 | 2025 | Braftovi, Mektovi, Tukysa |
| Pharmaessentia USA Corporation | $86.40 | 2024-2025 | Besremi |
| Sanofi-Aventis U.S. LLC | $79.95 | 2023 | |
| Adc Therapeutics America, INC. | $76.05 | 2024-2025 | |
| Taiho Oncology, INC. | $73.93 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.72 | 2025 | |
| Beigene USA, INC. | $64.01 | 2024-2025 | Brukinsa, Tevimbra |
| Emd Serono, INC. | $57.26 | 2025 | |
| Rigel Pharmaceuticals, INC. | $56.36 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| Sobi, INC | $47.17 | 2024-2025 | |
| Beone Medicines USA, INC. | $37.31 | 2025 | Brukinsa, Tevimbra |
| Genzyme Corporation | $37.15 | 2025 | |
| Kite Pharma, INC. | $32.77 | 2025 | Yescarta |
| Kyowa Kirin, INC. | $30.90 | 2024-2025 | Poteligeo |
| Janssen Pharmaceuticals, INC | $29.68 | 2023-2024 | Xarelto |
| Pharmaand Gmbh | $26.15 | 2025 | Rubraca |
| Tolmar, INC. | $26.15 | 2025 | Rubraca, Eligard |
| Tersera Therapeutics LLC | $24.63 | 2024 | Zoladex |
| Spectrum Pharmaceuticals INC. | $22.70 | 2025 | Rolvedon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Baird listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.